# The Recombinant Viral Capsid Protein rVP1 Induces Protective Immunity Against Coxsackievirus B3 (CVB3) Lethal Challenges in Balb/c Mouse Model

## TL;DR

A recombinant viral protein vaccine protects mice from a deadly virus causing heart and pancreas inflammation.

## Contribution

A recombinant VP1 protein vaccine was developed and shown to induce protective immunity against CVB3 in mice.

## Key findings

- The recombinant rVP1 protein elicited humoral and cellular immune responses in mice.
- The vaccine protected Balb/c mice from lethal CVB3 challenges.
- Neutralizing antibodies and INF-γ were produced in vaccinated mice.

## Abstract

Background/Objectives: Epidemiological studies have proven that coxsackievirus B3 (CVB3) is the major virus that causes acute and chronic myocarditis and pancreatitis. Currently, there are no antiviral therapeutic drugs or vaccines that are available for use as clinical therapeutics or vaccines. Subunit polypeptides-based vaccines, especially when combined with adjuvants, represent safe and effective vaccine platforms because they are considered to be better immunogens. The viral capsid protein VP1 of CVB3 is the most immunogenic viral polypeptide, providing opportunities for its use in designing subunit polypeptide vaccines. In the present study, we designed and produced a CVB3 vaccine candidate based on the recombinant expression of the major immunogenic viral protein VP1 of a wild-type CVB3 strain. Methods: We assessed its induced humoral and cellular immune responses and then evaluated its protective immunity against pathogenic CVB3 strain challenges in a Balb/c mouse model. Neutralizing specific antibodies and cytokine interferon gamma (INF-γ) production were determined in the sera of both prime- and prime-boost-immunized mice with the vaccine candidate. Results: Our results demonstrate that the recombinant rVP1 expressed in a eukaryotic insect cell baculovirus vector system elicited cellular and humoral immune responses, protecting Balb/c mice from lethal challenges. Conclusions: Hence, the vaccine produced based on the recombinant expression of VP1 is a promising and potential candidate against natural CVB3 infections.